| Clifford R. Jack | |
|---|---|
| Photo placeholder | |
| Affiliations | Mayo Clinic |
| Country | United States |
| Research Focus | Alzheimer's Disease, Mild Cognitive Impairment |
| Mechanisms | Amyloid Biomarkers, Tau Imaging, PET Imaging |
| H-index | 150+ |
Clifford R. Jack is a distinguished neurologist and researcher at Mayo Clinic, widely recognized for his pioneering work in Alzheimer's disease biomarkers, amyloid PET imaging, tau imaging, and longitudinal biomarker studies[1]. His contributions have fundamentally shaped our understanding of Alzheimer's disease progression and have been instrumental in developing the biomarkers model of Alzheimer's disease that guides current research and clinical practice.
Dr. Jack received his medical degree and completed neurology residency training before specializing in neurodegenerative disease research. At Mayo Clinic, he has established one of the world's leading programs in neuroimaging biomarkers for Alzheimer's disease. His work has been central to establishing international standards for Alzheimer's disease diagnosis and tracking through biomarker assessment.
Dr. Jack's research program focuses on understanding the temporal sequence of biomarker changes in Alzheimer's disease and developing imaging techniques for early diagnosis and disease tracking:
Biomarker Model of AD Progression: Developed the influential model showing the temporal sequence of biomarker changes in Alzheimer's disease, with amyloid changes occurring first, followed by tau, then neurodegeneration, and finally cognitive decline[2].
Tau PET Validation: Conducted critical validation studies showing that tau PET imaging accurately reflects neurofibrillary tangle pathology at autopsy.
Amyloid PET Standardization: Established standardized protocols for amyloid PET imaging that have been adopted internationally.
Longitudinal Biomarker Trajectories: Characterized how biomarkers change over time in individuals with normal cognition, mild cognitive impairment, and Alzheimer's disease.
Preclinical AD Definition: Helped define the preclinical stage of Alzheimer's disease based on biomarker evidence of amyloid accumulation in cognitively normal individuals.
Dr. Jack's development of the biomarker model of Alzheimer's disease progression has been transformative for the field. This model proposes that:
This framework has become foundational for understanding disease progression and has directly influenced clinical trial design, helping to identify individuals at the right stage for specific therapeutic interventions.
Dr. Jack has been instrumental in validating tau PET imaging as a biomarker for Alzheimer's disease. His research has demonstrated:
Through leadership in the Alzheimer's Disease Neuroimaging Initiative (ADNI) and other consortia, Dr. Jack has helped establish standardized protocols for:
These standardization efforts have enabled meaningful comparisons across studies and clinical trials.
Dr. Jack has led longitudinal studies tracking biomarker changes in individuals across the Alzheimer's disease spectrum. These studies have provided crucial insights into:
Dr. Jack has authored over 300 peer-reviewed publications, with seminal papers that have shaped Alzheimer's disease research:
Jack CR, et al. Longitudinal Tau PET in Aging and AD. Brain. 2018
Jack CR, et al. Amyloid-first and neurodegeneration-first profiles. Brain. 2020
Jack CR, et al. Defining imaging biomarkers in aging and AD. Nat Rev Neurol. 2020
Jack CR, et al. Rates of hippocampal atrophy in preclinical AD. Neurology. 2019
Jack CR, et al. Antemortem PET and neuropathology. Acta Neuropathol. 2019
Jack CR, et al. Amyloid and tau PET imaging in clinical practice. JAMA Neurol. 2021
Dr. Jack has held numerous leadership positions in Alzheimer's disease research:
As a senior researcher at Mayo Clinic, Dr. Jack has trained numerous graduate students, postdoctoral fellows, and clinical fellows in neuroimaging techniques and biomarker analysis. His mentorship has helped shape the next generation of Alzheimer's disease researchers, focusing on:
Dr. Jack has collaborated extensively with researchers at:
Current research in Dr. Jack's laboratory focuses on:
The study of Clifford R. Jack has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Mayo Clinic. Clifford R. Jack - Department of Neurology. https://www.mayoclinic.org ↩︎
Jack CR, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018. ↩︎